Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9

Drug Metabolism and Disposition

Volumn 29, Issue 11, 2001, Pages 1359-1361

  Wen, Xia ^a   Wang, Jun Sheng ^a   Backman, Janne T ^a   Kivistö, Kari T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; COUMARIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; ENZYME INHIBITOR; GEMFIBROZIL; GLIBENCLAMIDE; MEPHENYTOIN; MIDAZOLAM; PHENACETIN; TOLBUTAMIDE; WARFARIN;

ARTICLE; CONCENTRATION RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IC 50; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GEMFIBROZIL; HUMANS; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0034777840     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gemfibrozil interaction with warfarin sodium (coumadin)
2. Gemfibrozil: Interaction with glyburide
3. Plasma concentrations of active simvastatin acid are increased by gemfibrozil
4. Hypoglycemic agents
5. Gemfibrozil
6. In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: Interactions with other drugs
7. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
8. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
9. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
10. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia
11. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
12. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase
13. In vitro approaches to predicting drug interactions in vivo
14. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: Preferential inhibition of cytochrome P450 2C9
15. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers